EverSource Wealth Advisors
TLX icon

EverSource Wealth Advisors’s Telix Pharmaceuticals TLX Stock Holding History

EverSource Wealth Advisors’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.4K Buy
1,040
+84
+9% +$953 ﹤0.01% 2820
2026
Q2 		$11K Sell
956
-876
-48% -$8.92K ﹤0.01% 2853
2026
Q1 		$17.5K Buy
1,832
+934
+104% +$7.12K ﹤0.01% 2585
2025
Q4 		$6.73K Buy
898
+773
+618% +$7.44K ﹤0.01% 2986
2025
Q3 		$1.2K Buy
125
+58
+87% +$711 ﹤0.01% 3708
2025
Q2 		$1.08K Sell
67
-70
-51% -$1.18K ﹤0.01% 3715
2025
Q1 		$2.3K Buy
+137
New +$2.39K ﹤0.01% 2862

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return
Portland Investment Counsel
Portland Investment Counsel Burlington, Ontario, Canada $339M AUM 1.43% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Private Advisor Group
Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return
Raiffeisen Bank International
Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return
Aubrey Capital Management
Aubrey Capital Management Edinburgh, United Kingdom $115M AUM 51.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Brinker Capital Investments
Brinker Capital Investments Berwyn, Pennsylvania $17.5B AUM 20.48% 1-Year Est. Return

EverSource Wealth Advisors's TLX Position: Q3 2026 in Review

EverSource Wealth Advisors increased its Telix Pharmaceuticals (TLX) stake by 8.8% in Q3 2026, buying an estimated $953 and bringing the position to 1,040 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2820.

EverSource Wealth Advisors first reported a position in TLX in Q1 2025 and has held it in 7 quarters since. The position peaked at $17.5K in Q1 2026. 50 funds tracked by Wall St. Rank hold TLX as of Q3 2026.

  • EverSource Wealth Advisors held 1,040 shares of Telix Pharmaceuticals worth $11.4K as of Q3 2026.
  • EverSource Wealth Advisors bought 84 Telix Pharmaceuticals shares in Q3 2026, an estimated $953.
  • Telix Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q3 2026, its #2820 holding.
  • EverSource Wealth Advisors first reported a position in Telix Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
  • EverSource Wealth Advisors's Telix Pharmaceuticals position peaked at $17.5K in Q1 2026.
  • 50 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2026.

Based on EverSource Wealth Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.